ArticleFrontiers in oncology2025
A CART-based prognostic model for risk stratification of postoperative early recurrence in hepatocellular carcinoma with microvascular invasion.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Transcatheter Arterial Chemoembolization May Be Selectively Indicated as Postoperative Adjuvant Therapy for Hepatocellular Carcinoma Patients with Microvascular Invasion.Journal of hepatocellular carcinoma · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Postoperative early recurrence (ER) poses a major threat to long-term survival in hepatocellular carcinoma (HCC), especially in patients with microvascular invasion (MVI). Although conventional staging systems provide prognostic guidance, they are often inadequate for capturing recurrence risk in this high-risk subgroup. To develop and validate a CART-based prognostic model tailored to ER risk stratification and assessment of long-term outcomes following curative hepatectomy in MVI-positive HCC. Methods: A retrospective cohort of 440 patients with histologically confirmed HCC and MVI who underwent curative resection was analyzed. ER-associated predictors were identified via multivariable Cox regression and used to construct a classification and regression tree (CART) algorithm. Model discrimination, calibration, and clinical utility were evaluated using time-dependent ROC curves and decision curve analysis. Predictive performance for recurrence-free survival (RFS) and overall survival (OS) was compared against established staging systems. Results: Eight independent factors predictive of ER were identified: HBV-DNA load, tumor size, Edmondson-Steiner grade, tumor capsule integrity, MVI classification, satellite nodules, Ki-67 index, and CK19 expression. The CART model demonstrated robust discriminative ability (C-statistic: 0.773 in training; 0.764 in validation), and consistently outperformed conventional staging systems. Furthermore, CART-defined risk strata were significantly associated with both RFS and OS ( Conclusions: This CART-based framework provides a transparent and clinically implementable tool for ER risk stratification in MVI-positive HCC. By outperforming existing staging algorithms, it offers a basis for individualized surveillance and postoperative management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.